Therapy Areas: Oncology
AgilVax Expands series A-1 Financing
21 January 2020 - - US-based biopharmaceutical company AgilVax, Inc has closed an expansion of its series A-1 financing with an additional investment of USD 1.5m from its existing investors, the company said.

This brings the total capital raised to nearly USD 10m

AgilVax is a New Mexico biopharmaceutical company that discovers and develops targeted antibody-based products to treat multiple types of cancer.

The company has three development programmes; an antibody-drug conjugate targeting xCT, an unmodified monoclonal antibody targeting xCT, and AX09, a VLP-based xCT vaccine.
Login
Username:

Password: